Hi again Midas,
Regards this PR, I don't think there is anything new or particularly interesting to glean from it.
The key point in the PR is:
"Dr. Papp who is leading the design of Can-Fite’s pivotal Phase III psoriasis registration trial, which will be submitted to the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for market clearance of Piclidenoson in the treatment of moderate to severe psoriasis."
On this there are 2 things to see.
1. They are clearly designing the new Phase 3 Psoriasis study with Dr. Papp. So we are years off from getting an outcome on the psoriasis situation.
2. They appear to be stuck with their beefed up previous PR wording where to calm and I dare say confused sentiment, they keep adding in buzz wording about registration trial and submission to FDA and EMA to keep people thinking they are moving ahead with some sort of speed. However as we know this is not the case. First they will design, then recruit then get data read out, all of which will take years and plenty more money to get there in this indication.
The liver cancer study, while still being at least a year off, is the closest thing I see on the horizon.
News 
Market Data 
Discover 
